Skip to Content

Amicus Therapeutics Inc FOLD

Morningstar Rating
$10.71 −0.11 (1.02%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

FOLD is trading at a 8% discount.
Price
$10.89
Fair Value
$66.43
Uncertainty
High
1-Star Price
$76.28
5-Star Price
$5.75
Economic Moat
Kyl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FOLD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$10.82
Day Range
$10.6810.93
52-Week Range
$9.7014.57
Bid/Ask
$10.15 / $10.75
Market Cap
$3.16 Bil
Volume/Avg
5.1 Mil / 3.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
7.92
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
517

Competitors

Valuation

Metric
FOLD
BMRN
Price/Earnings (Normalized)
107.85
Price/Book Value
19.643.40
Price/Sales
7.927.09
Price/Cash Flow
34.58
Price/Earnings
FOLD
BMRN

Financial Strength

Metric
FOLD
BMRN
Quick Ratio
2.231.45
Current Ratio
2.882.51
Interest Coverage
−2.138.78
Quick Ratio
FOLD
BMRN

Profitability

Metric
FOLD
BMRN
Return on Assets (Normalized)
−5.21%6.15%
Return on Equity (Normalized)
−30.55%8.47%
Return on Invested Capital (Normalized)
−0.78%6.27%
Return on Assets
FOLD
BMRN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFjbnwlncwfHkdb$557.8 Bil
VRTX
Vertex Pharmaceuticals IncQbchslwGnlnyh$103.3 Bil
REGN
Regeneron Pharmaceuticals IncFfchfmltDhzzhn$98.8 Bil
MRNA
Moderna IncBqtgpqjqXhmr$38.8 Bil
ARGX
argenx SE ADRRvdnckmzXby$21.3 Bil
BNTX
BioNTech SE ADRXmfwymmhpCjxnm$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncBjwxttdxLcrtc$18.4 Bil
BMRN
Biomarin Pharmaceutical IncBtqvmpsKwfwkj$17.5 Bil
RPRX
Royalty Pharma PLC Class AFwvrwjxbrCcfwx$12.4 Bil
INCY
Incyte CorpBlyzngjyyJxrmfc$11.9 Bil

Sponsor Center